OXFORD, England, November 19, 2013 /PRNewswire/ --
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of two new open access journals in its cardiology journals series: International Journal of Cardiology-Heart & Vessels andInternational Journal of Cardiology-Metabolic & Endocrine.
Heart disease is the leading cause of deaths worldwide, with nearly 600,000 deaths in the US alone in 2011, according to the United States Centers for Disease Control and Prevention. Both new journals will publish essential research in the field of cardiology open access, enabling the latest research to be freely available worldwide.
"With 12.9 million deaths from ischaemic heart disease and stroke in 2010, representing a quarter of total deaths*, considerable research is taking place to diagnose and treat this condition, and others such as hypertension and thrombosis," said Prof. Michael Henein, Umeå Heart Centre, Sweden, Editor-in-Chief of the International Journal of Cardiology (IJC): Heart & Vessels.
"The new journal will be the natural home for this field of research, publishing articles and reviews on structural and functional cardiovascular pathology, with an emphasis on cardiovascular imaging, disease pathophysiology and management," Prof. Henein continued. "I am honored to be appointed Editor-in-Chief of this journal and would like to invite researchers in these fields to submit their best papers for consideration."
Prof. Giuseppe Rosano, of the IRCCS San Raffaele Pisana, Italy, will serve as Editor-in-Chief of International Journal of Cardiology (IJC): Metabolic & Endocrine which will be devoted to cardiovascular medicine in general and to the interplay between the cardiovascular system metabolism and hormones in particular. The journal will also publish articles reporting the effect of clinical trials and therapeutic interventions affecting the metabolic and/or hormonal influences on the cardiovascular system.
"The journal will have a specific focus on the cardiovascular effects of diseases with mixed metabolic and endocrine pathophysiology, such as arterial hypertension and diabetes mellitus. It will serve the interests of both practising clinicians and researchers," specified Prof. Rosano.
"We are delighted to support this important and ever-expanding research field with the launch of two new titles in our International Journal of Cardiology series", added Tamara Lucas, Publisher at Elsevier.
*Lozano, R. Global Burden of Disease study in 2010, The Lancet, Vol. 380, Issue 9859, Pages 2095-2128, 15 December 2012.
About Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 70 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.